| 货号 | 15214-5mg |
| 描述 | Aldose reductase, the first enzyme of the polyol pathway, converts glucose to sorbitol in the presence of NADPH. Increased aldose reductase expression, induced by hyperglycemia, has been associated with complications of diabetes, as it can create a metabolic imbalance in tissues dependent on insulin for the uptake of glucose. Epalrestat is a carboxylic acid-based inhibitor of aldose reductase (IC50 = 0.01-15 μM).1 At 10 nM, it can suppress high glucose-induced proliferation of vascular smooth muscle cells and at 100 nM it can prevent high glucose-induced intracellular NADH/NAD+ increase and membrane-bound protein kinase C activation.2,3 Epalrestat has been shown to reduce oxidative stress in type 2 diabetic patients, significantly decreasing lipid hydroperoxide levels in erythrocytes when administered at 150 mg/day.4 |
| 别名 | Kinedak;ONO-2235;Sorbistat; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Miyamoto, S. Molecular modeling and structure-based drug discovery studies of aldose reductase inhibitors. Chem-Bio Informatics Journal 2(3), 74-85 (2002). 2.Yasunari, K.,Kohno, M.,Kano, H., et al. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose. Hypertension 35(5), 1092-1098 (2000). 3.Yasunari, K.,Kohno, M.,Kano, H., et al. Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Arteriosclerosis, Thrombosis, and Vascular Biology 15(12), 2207-2212 (1995). 4.Ohmura, C.,Watada, H.,Azuma, K., et al. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes. Endocrine Journal 56(1), 149-156 (2009). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 319.4 |
| 分子式 | C15H13NO3S2 |
| CAS号 | 82159-09-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |